Roth Capital Issues Optimistic Estimate for MGRM Earnings

Monogram Orthopaedics, Inc. (NASDAQ:MGRMFree Report) – Roth Capital raised their Q1 2025 earnings estimates for Monogram Orthopaedics in a research note issued on Thursday, March 13th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.11). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Monogram Orthopaedics’ current full-year earnings is ($0.49) per share. Roth Capital also issued estimates for Monogram Orthopaedics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($0.70) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.30) EPS, FY2026 earnings at ($0.63) EPS and FY2027 earnings at ($0.24) EPS.

Separately, Roth Mkm started coverage on shares of Monogram Orthopaedics in a research report on Monday, December 9th. They set a “buy” rating and a $4.00 price target for the company.

View Our Latest Research Report on MGRM

Monogram Orthopaedics Stock Up 0.9 %

Shares of NASDAQ:MGRM opened at $2.33 on Monday. The company has a market cap of $79.95 million, a P/E ratio of -4.96 and a beta of 1.66. Monogram Orthopaedics has a 52 week low of $1.53 and a 52 week high of $4.90. The company has a 50-day moving average price of $2.54 and a 200 day moving average price of $2.49.

Monogram Orthopaedics (NASDAQ:MGRMGet Free Report) last announced its quarterly earnings data on Wednesday, March 12th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03.

Institutional Investors Weigh In On Monogram Orthopaedics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in shares of Monogram Orthopaedics during the 4th quarter valued at approximately $25,000. Wells Fargo & Company MN raised its position in shares of Monogram Orthopaedics by 286.6% during the 4th quarter. Wells Fargo & Company MN now owns 11,597 shares of the company’s stock worth $27,000 after purchasing an additional 8,597 shares during the last quarter. Barclays PLC acquired a new position in shares of Monogram Orthopaedics during the 3rd quarter worth approximately $29,000. Orion Portfolio Solutions LLC acquired a new position in shares of Monogram Orthopaedics during the 4th quarter worth approximately $31,000. Finally, State Street Corp acquired a new position in shares of Monogram Orthopaedics during the 3rd quarter worth approximately $62,000. 0.45% of the stock is currently owned by institutional investors and hedge funds.

About Monogram Orthopaedics

(Get Free Report)

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.

Featured Articles

Earnings History and Estimates for Monogram Orthopaedics (NASDAQ:MGRM)

Receive News & Ratings for Monogram Orthopaedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monogram Orthopaedics and related companies with MarketBeat.com's FREE daily email newsletter.